Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282959967> ?p ?o ?g. }
- W4282959967 endingPage "713" @default.
- W4282959967 startingPage "706" @default.
- W4282959967 abstract "Bone morphogenetic protein (BMP) is a costly agent commonly used in spine surgery. Its effectiveness and complication profile have never been studied in a large, propensity-matched population following its approval by the Food and Drug Administration for use in single-level anterior lumbar interbody fusion (ALIF) surgeries.To investigate the rate of symptomatic pseudarthrosis or need for revision surgery after single-level stand-alone ALIFs with and without the use of BMP.Medicare Standard Analytic files derived from Medicare parts A and B were used to identify adult patients who underwent single-level ALIF procedures with and without use of BMP between 2004 and 2014. Patients were propensity matched based on their age, gender, and history of diabetes mellitus, hypertension, chronic kidney disease, body mass index greater than 30 kg/m2, smoking, rheumatoid arthritis, and osteoporosis. Sensitivity analysis using adjusted multivariate logistic regression models was also performed. The primary outcomes were the rates of symptomatic pseudarthrosis or need for revision surgery.The propensity-matched population analyzed in this study contained 22,380 patients undergoing single-level ALIF (8971 [40.6%] with BMP and 13,139 [59.4%] without BMP). Both patient groups were balanced at baseline. The rate of symptomatic pseudarthrosis in the propensity-matched analysis was higher in the BMP group (1.9% vs 1.4%, P < 0.05). BMP use during single-level ALIFs was associated with 44% increased odds of developing pseudarthrosis (OR 1.44, 95% CI 1.16-1.76). However, there was no statistically significant difference in the rate of revision surgery between groups (3.7% vs 3.5%, P = 0.49).BMP use in single-level ALIFs may be associated with increased risk of symptomatic pseudarthrosis. Large prospective pragmatic trials are needed to corroborate our findings." @default.
- W4282959967 created "2022-06-17" @default.
- W4282959967 creator A5021230689 @default.
- W4282959967 creator A5024268828 @default.
- W4282959967 creator A5061025039 @default.
- W4282959967 creator A5072774308 @default.
- W4282959967 creator A5076123107 @default.
- W4282959967 creator A5082443716 @default.
- W4282959967 creator A5083543188 @default.
- W4282959967 date "2022-06-14" @default.
- W4282959967 modified "2023-09-30" @default.
- W4282959967 title "Bone Morphogenetic Protein in Anterior Lumbar Interbody Fusions: A Propensity-Matched Medicare Outcome Analysis" @default.
- W4282959967 cites W1486382450 @default.
- W4282959967 cites W1966469600 @default.
- W4282959967 cites W1966639987 @default.
- W4282959967 cites W1968450106 @default.
- W4282959967 cites W1970221292 @default.
- W4282959967 cites W1971546465 @default.
- W4282959967 cites W1975156603 @default.
- W4282959967 cites W1979340915 @default.
- W4282959967 cites W1979682230 @default.
- W4282959967 cites W1980200272 @default.
- W4282959967 cites W1988538920 @default.
- W4282959967 cites W1994568570 @default.
- W4282959967 cites W1995480990 @default.
- W4282959967 cites W1998216604 @default.
- W4282959967 cites W1999829265 @default.
- W4282959967 cites W2000336408 @default.
- W4282959967 cites W2004110585 @default.
- W4282959967 cites W2008294515 @default.
- W4282959967 cites W2009743923 @default.
- W4282959967 cites W2015279823 @default.
- W4282959967 cites W2027003318 @default.
- W4282959967 cites W2034291729 @default.
- W4282959967 cites W2035408362 @default.
- W4282959967 cites W2035743173 @default.
- W4282959967 cites W2036358360 @default.
- W4282959967 cites W2037693907 @default.
- W4282959967 cites W2039839585 @default.
- W4282959967 cites W2043199083 @default.
- W4282959967 cites W2050153843 @default.
- W4282959967 cites W2050622412 @default.
- W4282959967 cites W2051068441 @default.
- W4282959967 cites W2051414433 @default.
- W4282959967 cites W2053230003 @default.
- W4282959967 cites W2057067590 @default.
- W4282959967 cites W2058607697 @default.
- W4282959967 cites W2059053909 @default.
- W4282959967 cites W2060910232 @default.
- W4282959967 cites W2069244770 @default.
- W4282959967 cites W2072905377 @default.
- W4282959967 cites W2074645659 @default.
- W4282959967 cites W2087864134 @default.
- W4282959967 cites W2105810475 @default.
- W4282959967 cites W2125728570 @default.
- W4282959967 cites W2128132349 @default.
- W4282959967 cites W2130023694 @default.
- W4282959967 cites W2139124835 @default.
- W4282959967 cites W2140102422 @default.
- W4282959967 cites W2140810539 @default.
- W4282959967 cites W2151975561 @default.
- W4282959967 cites W2154128099 @default.
- W4282959967 cites W2156097368 @default.
- W4282959967 cites W2159404520 @default.
- W4282959967 cites W2168783188 @default.
- W4282959967 cites W2184143792 @default.
- W4282959967 cites W2200312595 @default.
- W4282959967 cites W2223768634 @default.
- W4282959967 cites W2314272269 @default.
- W4282959967 cites W2325239839 @default.
- W4282959967 cites W2328838959 @default.
- W4282959967 cites W2332287991 @default.
- W4282959967 cites W2333493293 @default.
- W4282959967 cites W2436369429 @default.
- W4282959967 cites W2462565678 @default.
- W4282959967 cites W2604564545 @default.
- W4282959967 cites W2605720262 @default.
- W4282959967 cites W2615034379 @default.
- W4282959967 cites W2721984505 @default.
- W4282959967 cites W2921147963 @default.
- W4282959967 cites W2923868934 @default.
- W4282959967 cites W2958839650 @default.
- W4282959967 cites W4239350227 @default.
- W4282959967 doi "https://doi.org/10.14444/8301" @default.
- W4282959967 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35705214" @default.
- W4282959967 hasPublicationYear "2022" @default.
- W4282959967 type Work @default.
- W4282959967 citedByCount "0" @default.
- W4282959967 crossrefType "journal-article" @default.
- W4282959967 hasAuthorship W4282959967A5021230689 @default.
- W4282959967 hasAuthorship W4282959967A5024268828 @default.
- W4282959967 hasAuthorship W4282959967A5061025039 @default.
- W4282959967 hasAuthorship W4282959967A5072774308 @default.
- W4282959967 hasAuthorship W4282959967A5076123107 @default.
- W4282959967 hasAuthorship W4282959967A5082443716 @default.
- W4282959967 hasAuthorship W4282959967A5083543188 @default.
- W4282959967 hasBestOaLocation W42829599671 @default.
- W4282959967 hasConcept C126322002 @default.
!["Bone morphogenetic protein (BMP) is a costly agent commonly used in spine surgery. Its effectiveness and complication profile have never been studied in a large, propensity-matched population following its approval by the Food and Drug Administration for use in single-level anterior lumbar interbody fusion (ALIF) surgeries.To investigate the rate of symptomatic pseudarthrosis or need for revision surgery after single-level stand-alone ALIFs with and without the use of BMP.Medicare Standard Analytic files derived from Medicare parts A and B were used to identify adult patients who underwent single-level ALIF procedures with and without use of BMP between 2004 and 2014. Patients were propensity matched based on their age, gender, and history of diabetes mellitus, hypertension, chronic kidney disease, body mass index greater than 30 kg/m2, smoking, rheumatoid arthritis, and osteoporosis. Sensitivity analysis using adjusted multivariate logistic regression models was also performed. The primary outcomes were the rates of symptomatic pseudarthrosis or need for revision surgery.The propensity-matched population analyzed in this study contained 22,380 patients undergoing single-level ALIF (8971 [40.6%] with BMP and 13,139 [59.4%] without BMP). Both patient groups were balanced at baseline. The rate of symptomatic pseudarthrosis in the propensity-matched analysis was higher in the BMP group (1.9% vs 1.4%, P < 0.05). BMP use during single-level ALIFs was associated with 44% increased odds of developing pseudarthrosis (OR 1.44, 95% CI 1.16-1.76). However, there was no statistically significant difference in the rate of revision surgery between groups (3.7% vs 3.5%, P = 0.49).BMP use in single-level ALIFs may be associated with increased risk of symptomatic pseudarthrosis. Large prospective pragmatic trials are needed to corroborate our findings."](?object=%22Bone%20morphogenetic%20protein%20(BMP)%20is%20a%20costly%20agent%20commonly%20used%20in%20spine%20surgery.%20Its%20effectiveness%20and%20complication%20profile%20have%20never%20been%20studied%20in%20a%20large%2C%20propensity-matched%20population%20following%20its%20approval%20by%20the%20Food%20and%20Drug%20Administration%20for%20use%20in%20single-level%20anterior%20lumbar%20interbody%20fusion%20(ALIF)%20surgeries.To%20investigate%20the%20rate%20of%20symptomatic%20pseudarthrosis%20or%20need%20for%20revision%20surgery%20after%20single-level%20stand-alone%20ALIFs%20with%20and%20without%20the%20use%20of%20BMP.Medicare%20Standard%20Analytic%20files%20derived%20from%20Medicare%20parts%20A%20and%20B%20were%20used%20to%20identify%20adult%20patients%20who%20underwent%20single-level%20ALIF%20procedures%20with%20and%20without%20use%20of%20BMP%20between%202004%20and%202014.%20Patients%20were%20propensity%20matched%20based%20on%20their%20age%2C%20gender%2C%20and%20history%20of%20diabetes%20mellitus%2C%20hypertension%2C%20chronic%20kidney%20disease%2C%20body%20mass%20index%20greater%20than%2030%20kg%2Fm2%2C%20smoking%2C%20rheumatoid%20arthritis%2C%20and%20osteoporosis.%20Sensitivity%20analysis%20using%20adjusted%20multivariate%20logistic%20regression%20models%20was%20also%20performed.%20The%20primary%20outcomes%20were%20the%20rates%20of%20symptomatic%20pseudarthrosis%20or%20need%20for%20revision%20surgery.The%20propensity-matched%20population%20analyzed%20in%20this%20study%20contained%2022%2C380%20patients%20undergoing%20single-level%20ALIF%20(8971%20%5B40.6%25%5D%20with%20BMP%20and%2013%2C139%20%5B59.4%25%5D%20without%20BMP).%20Both%20patient%20groups%20were%20balanced%20at%20baseline.%20The%20rate%20of%20symptomatic%20pseudarthrosis%20in%20the%20propensity-matched%20analysis%20was%20higher%20in%20the%20BMP%20group%20(1.9%25%20vs%201.4%25%2C%20P%20%3C%200.05).%20BMP%20use%20during%20single-level%20ALIFs%20was%20associated%20with%2044%25%20increased%20odds%20of%20developing%20pseudarthrosis%20(OR%201.44%2C%2095%25%20CI%201.16-1.76).%20However%2C%20there%20was%20no%20statistically%20significant%20difference%20in%20the%20rate%20of%20revision%20surgery%20between%20groups%20(3.7%25%20vs%203.5%25%2C%20P%20%3D%200.49).BMP%20use%20in%20single-level%20ALIFs%20may%20be%20associated%20with%20increased%20risk%20of%20symptomatic%20pseudarthrosis.%20Large%20prospective%20pragmatic%20trials%20are%20needed%20to%20corroborate%20our%20findings.%22){kind=link}